The SANOVO data de-risk the Tagrisso+Orpathys first-line regulatory path in China and strengthen the overall Tagrisso franchise against emerging EGFR-TKI competition. Traders should watch for regulatory submission timelines in China and potential global filings; the SAFFRON global readout in the post-Tagrisso setting further supports the combination's broad utility. Near-term catalyst is data presentation at a medical meeting.
Price Chart
Executive Summary
AstraZeneca announced positive Phase III SANOVO trial results showing Tagrisso plus Orpathys achieved a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) versus Tagrisso alone in first-line MET-overexpressing EGFR-mutated NSCLC. The combination also showed encouraging overall survival benefit. These data extend the all-oral combination into the first-line setting, reinforcing Tagrisso's backbone role and supporting regulatory submissions in China.
Key Facts
- SANOVO Phase III trial met primary endpoint: statistically significant and highly clinically meaningful PFS improvement for Tagrisso + Orpathys vs Tagrisso alone in 1L EGFRm MET-overexpressing NSCLC.
- PFS benefit demonstrated in both high MET (IHC 3+) and ITT (IHC 2+, IHC 3+) populations.
- Overall survival, a secondary endpoint, showed very encouraging clinical benefit; trial continuing follow-up.
- Safety profile consistent with known profiles of each medicine; no new safety findings.
- Data will be presented at a forthcoming medical meeting and shared with regulatory authorities.
- Combination already approved in China for post-EGFR-TKI MET-amplified patients (SACHI trial) and recently reported positive SAFFRON global Phase III results in post-Tagrisso setting.
- Orpathys is jointly developed by AstraZeneca and HUTCHMED, commercialized by AstraZeneca.
Financial Impact
Positive Phase III data in 1L EGFRm NSCLC with MET overexpression expands addressable patient population for Tagrisso + Orpathys combination; Tagrisso is a multi-billion-dollar franchise and this label extension supports revenue durability against competitive pressure.
Risk Factors
- Regulatory approval in China is not guaranteed; SANOVO is a China-only trial and may require additional global data for ex-China filings.
- Competitive landscape includes other EGFR-MET bispecific antibodies and combination approaches that could limit market share.
- Overall survival data are still immature; final OS readout could alter the risk/benefit profile.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007983 |
| Document: 0001654954-26-007983-index-headers.html | 0001654954-26-007983 |
| Document: 0001654954-26-007983-index.html | 0001654954-26-007983 |
| Document: 0001654954-26-007983.txt | 0001654954-26-007983 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $157.02 (−2.98%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $157.02 (+4.13%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $157.02 (−1.89%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $157.02 (+3.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access